EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group

被引：54

作者：

Dirix, LY

Tonnesen, F

Cassidy, J

Epelbaum, R

Huinink, WWT

Pavlidis, N

Sorio, R

Gamucci, T

Wolff, I

TeVelde, A

Lan, J

Verweij, J

机构：

[1] HERLEV UNIV HOSP,DK-2730 HERLEV,DENMARK

[2] UNIV GLASGOW,GLASGOW,LANARK,SCOTLAND

[3] RAMBAM MED CTR,HAIFA,ISRAEL

[4] NETHERLANDS CANC INST,AMSTERDAM,NETHERLANDS

[5] UNIV HOSP IOANNINA,IOANNINA,GREECE

[6] CTR RIFERIMENTO ONCOL,I-33081 AVIANO,ITALY

[7] REGINA ELENA INST CANC RES,I-00161 ROME,ITALY

[8] MED KLIN,NURNBERG,GERMANY

[9] NEW DRUG DEV OFF,AMSTERDAM,NETHERLANDS

[10] ROTTERDAM CANC INST,ROTTERDAM,NETHERLANDS

来源：

EUROPEAN JOURNAL OF CANCER | 1996年 / 32A卷 / 11期

关键词：

E09; breast cancer; pancreatic cancer; gastric cancer; colorectal cancer; proteinuria; renal toxicity; phase II study;

D O I：

10.1016/0959-8049(96)00226-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, pancreatic and colorectal cancer. EO9 was given as a 5 min i.v. infusion at a weekly dose of 12 mg/m(2). 92 patients were entered; 22 with breast cancer, 26 with colon cancer, 24 with pancreatic cancer and 20 with gastric cancer. In general, the drug was well tolerated with nausea and vomiting occurring in 26.42 and 13.3% of courses, respectively. Reversible proteinuria was the main toxicity occurring in 45% of courses. Antitumour activity was not observed. At this dose and schedule, EO9 is not an active drug in the type of tumour studied. Copyright (C) 1996 Elsevier Science Ltd

引用

页码：2019 / 2022

页数：4

共 12 条

[1] EO9 - RELATIONSHIP BETWEEN DT-DIAPHORASE LEVELS AND RESPONSE IN-VITRO AND IN-VIVO [J].